Laboratorios Rovi : Q3 2023 preview. Target price raised on higher Okedi/Risvan visibility
>Sales momentum to improve sequentially as heparins recover, Okedi ramps up and CMO keeps a stiff upper lip - The company is due to publish its Q3 2023 results on 8 November before the market opens. We now expect sales to improve in terms of q-o-q momentum, delivering +6% growth to € 206m (vs +2% in Q2 and -2% in Q1) which is explained by heparins posting some sequential improvement, Okedi being launched in several European markets and CMO weathering lower Covid vacci...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.